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Abstract
Background
Serum infliximab (IFX) and antibody-to-infliximab (ATI) levels are objective parameters, that
may have a great role in the therapeutic decisions during maintenance biological therapy.
Research design and methods
48 inflammatory bowel disease patients receiving maintenance IFX therapy were prospec-
tively enrolled and divided into adequate (complete remission N = 20) and inadequate
responder (partial response, loss of response, dose escalation; N = 28) groups. Blood sam-
ples were collected just before (trough level, TL) and two (W2aTL) and six weeks (W6aTL)
after the administration of IFX.
Results
Single measurement of ATI titer was insufficient for predicting therapeutic response due
to transient expression of ATI, however, using the three points’ measurements, significant
difference has been detected between the adequate and inadequate responder group
(5.0% vs 35.7%; p = 0.016). The mean value of TL was significantly higher in the adequate
responder group (3.11±1.64 vs.1.19±1.11; p<0.001) without further difference on the sec-
ond and sixth week. Sensitivity and specificity for predicting the therapeutic response were
85.0% and 71.4% based on the cut-off value of TL 2.0 μg/ml.
Conclusion
Simultaneous measurement of serum IFX level prior to administration of regular IFX infusion
and ATI titers significantly increase the diagnostic accuracy for the therapeutic decision in
patients uncertainly responding to the therapy. The measurement of W2aTL and W6aTL
levels did not result in further improvement in the prediction of therapeutic response.
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Introduction
The introduction of biological treatment has made a major break through in the management
of inflammatory bowel disease (IBD). However, a substantial number of patients show only
partial response, and approximately 20–45% of the primary responders show loss of efficacy
[1–4]. Cessation of therapy or switching to another biological drug currently depends mainly
on subjective clinical judgement. Serum infliximab (IFX) and antibody-to-infliximab (ATI)
levels are objective parameters that may help in the therapeutic decisions during maintenance
biological therapy. Results of recent studies suggest that serum IFX concentration predicts
long-term clinical response [5]. In ulcerative colitis (UC), detectable IFX trough level (TL) is
associated with higher rate of clinical remission and endoscopic improvement and with lower
risk of colectomy [6]. ATI is reported to develop up to 60% of IBD patients during mainte-
nance IFX therapy [7,8]. The presence of ATI is associated with lower serum IFX levels, higher
rate of infusion reactions and loss of response, and it may shorten the effect of IFX infusions
[7,9].
Despite the proven importance of serum IFX and ATI levels in the prediction of clinical
response, it is still not clearly defined when and how frequently we have to measure these titers.
Therefore, the aim of this study was to determine the optimal timing and frequency of serum
IFX and ATI measurements. We aimed to assess the correlation between serum IFX and ATI
levels and response to IFX therapy and to determine the accuracy of serum drug concentration
measurement in the prediction of the long-term clinical response.
Patients and methods
Forty-eight consecutive, adult IBD patients receiving IFX maintenance therapy were prospec-
tively enrolled between March 2014 and October 2015 in a Hungarian tertiary referral medical
center. All patients received detailed written and verbal information about the investigation,
and they consented to participation in this study. The protocol was approved by the Regional
and Institutional Human Medical Biological Research Ethics Committee of the University of
Szeged (SZTE: 169/2011). The study was carried out under the declaration of Helsinki.
IFX was administered intravenously with maintenance dosage of 5 or 10 mg/kg every 8
weeks as monotherapy or in combination with azathioprine, 5-aminosalicylates and/or corti-
costeroids. In our study no distinction has been made between original and biosimilar IFX,
because previous studies did not find any difference in terms of efficacy, safety and immunoge-
nicity between the original and biosimilar agent [10–12]. Patients were divided into adequate
and inadequate responder groups based on their clinical response at inclusion, which was
determined with partial Mayo Score (pMayo) and Crohn’s Disease Activity Index (CDAI).
Adequate response was defined as complete clinical remission with pMayo score2 or CDAI
score <150 during the previous 6 months on maintenance therapy. Patients were categorized
into the inadequate responder group, if: 1) they partially responded to 5 mg/kg dose IFX ther-
apy (a decrease in pMayo score of3 points or in CDAI score of 100 point from baseline); 2)
dose escalation was required (10 mg/kg body weight) during the previous 6 months; 3) loss of
response occurred at inclusion. The baseline was the time when patient received the first IFX
infusion, so response correspond to changes of scores during the biological therapy.
Blood samples were collected for serum IFX and ATI measurements at inclusion–immedi-
ately prior the administration of regular maintenance IFX infusion (trough level, TL)–, as well
as 2 (W2aTL) and 6 weeks (W6aTL) afterwards. Serum samples were tested by quantitative
enzyme-linked immunosorbent assay (ELISA) with LISA-Tracker (Theradiag, France). The
detectable serum IFX level was 0.1 μg/ml. In case of LISA TRACKER, the measurement range
was 10 to 200 ng/mL for antibodies and > 10 ng/mL was considered to be positive. At the end
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of the 6-months follow-up the response to IFX therapy was re-evaluated by using pMayo and
CDAI scoring system.
Patients’ demographic data, clinical characteristics, previous surgery and concomitant med-
ications were collected using MedSolution medical recorder. Statistical tests were performed
using R statistical software version 3.3.1 (R Foundation) and SPSS software version 24 (SPSS
Inc., Chicago, Illinois, USA), values of p<0.05 were considered statistically significant. Differ-
ences in continuous variables such as serum IFX level, disease duration, age at the diagnosis
were assessed with Welch Two Sample t-test. Fisher’s Exact Test were used to compare the
proportion of categorical variables in the adequate and inadequate responder group (ATI posi-
tivity, type of disease, gender, concomitant treatment). The cut-off levels were determined by
receiver operating characteristic (ROC) curve analysis, which used clinical remission as a clas-
sification variable to calculate the sensitivity, specificity and area under the ROC curve (AUC).
Multivariate models were constructed using logistic regression (Overall model fit was
described with Nagelkerke R2, and the goodness-of-fit by use of Hosmer and Lemeshow Test).
Descriptive statistics were reported as mean, median and interquartile range, categorical vari-
ables were expressed as percentage.
Results
Patient characteristics at inclusion
The adequate responder group consisted of 20 patients being in sustained clinical remission
on maintenance IFX therapy. The inadequate responder group (N = 28) was heterogeneous: 8
patients showed chronic activity during the last 6 months of IFX maintenance therapy with
mild (N = 7) or moderate (N = 1) disease activity. Fourteen patients required dose escalation
(10 mg/kg) in the last 6 months: 3 of them were in remission, in 10 cases mild and in one case
moderate activity was observed at the time of inclusion. Six patients had relapse at the time of
the first sampling (TL).
Forty-two patients received original and 6 patients received biosimilar IFX (4 inadequate
and 2 adequate responder). IFX monotherapy was applied in only one third of patients (N =
16), in the remaining cases it was complemented by azathioprine (N = 26), 5-aminosalicylates
(N = 10), local (N = 3) and/or systemic corticosteroids (N = 6). There was no significant pro-
portional variance regarding gender, mean age at the diagnosis and disease duration between
the groups (Table 1). Rate of Crohn’s disease (CD) patients were higher in the inadequate
responder group, but the difference was not statistically relevant, and the demographic and
clinical characteristics between UC and CD patients did not differ significantly.
Serum IFX levels
Serum IFX level was measured three times (TL, W2aTL, W6aTL) during the administration of
regular maintenance infusion. The mean value of serum TL was significantly higher in the ade-
quate vs. inadequate responder group (3.11±1.64 vs.1.19±1.11; p<0.001). Mean IFX levels did
not differ between the groups at week 2 (18.87±39.05 vs. 16.99±27.65; p = 0.854) and week 6
(3.69±3.96 vs. 1.74±2.15; p = 0.055) (Fig 1). Therefore, W2aTL and W6aTL levels were not
suitable for the prediction of therapeutic response. According to ROC analysis, the cut-off
value of TL for predicting therapeutic response was 2.0 μg/ml with 85.0% sensitivity and 74.1%
specificity. The AUC was 84.7% (Fig 2). In the inadequate responder group,2.0 μg/ml TL
was measured in 8 cases: six patients received intensified IFX therapy (10mg/kg every 8 weeks)
from which five patients responded to the dose escalation. One of the three adequate re-
sponders with low IFX level and ATI positivity developed allergic reaction, the remaining two
patients with low IFX level without ATI positivity were in clinical remission. (Fig 3) The results
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of multivariate analysis (TL, W2aTL, W6aTL levels and ATI positivity) performed by logistic
regression revealed prediction rate of 85.4% for the current response (Table 2). It showed high
similarity with the results of ROC analysis, which assessed only the TL. Therefore, measure-
ment of W2aTL and W6aTL levels did not improve the accuracy of prediction of therapeutic
response.
Response to biological therapy was reevaluated after the 6-months follow-up. Five inade-
quate responders were re-classified into the adequate responder group. In one of them optimal
serum IFX level was measured without ATI positivity. The clinical data of the patient suggested
an ongoing infection at the time of the inclusion, which resolved after the administration of
antibiotics. In two cases with dose escalation at inclusion, serum W2aTL level was higher than
2 μg/ml, but the drug concentration dropped rapidly to an almost undetectable level by week
6. In these cases, ATI expression was also detectable, which suggests an accelerated drug elimi-
nation from the circulation. Despite TL not reaching the cut-off value (1.71 μg/ml and 0.83 μg/
ml), two patients showed complete clinical remission. No ATI expression was detectable in
Table 1. Clinical and demographic data of 48 enrolled inflammatory bowel disease patients.
Clinical and demographic data of patients (N = 48)
Adequate responder (N = 20) Inadequate responder (N = 28)
Female/male (N˚) 10/10 13/15
UC/CD (N˚) 9/11 7/21
Ulcerative colitis
• pancolitis 4 (20%) 4 (14.3%)
• left-sided colitis 5 (25%) 3 (10.7%)
Crohn’s Disease
• ileal (L1) - 2 (7.1%)
• colonic (L2) 4 (20%) 11 (39.3%)
• ileocolonic (L3) 7 (35%) 8 (28.6%)
• non stricturing, non penetrating (B1) 4 (20%) 8 (28.6%)
• stricturing (B2) 2 (10%) 3 (10.7%)
• penetrating (B3) 5 (25%) 10 (35.7%)
• perianal (p) 7 (35%) 9 (32.1%)
Age at the diagnosis (years) 25.00±9.21 26.29±9.78
Disease duration (years) 9.14±5.32 7.40±5.35
Duration of infliximab therapy
• < 1 year 7 (35%) 5 (17.9%)
• 1–2 years 8 (40%) 11 (39.3%)
• > 2 years 5 (25%) 12 (42.9%)
Previous surgery (N˚; %) 7 (35%) 14 (50%)
• Seton drainage 6 (30%) 9 (32.1%)
• Intraabdominal fistula - 2 (7.1%)
• Ileocecal resection 1 (5%) 3 (15%)
• Right hemicolectomy - 1 (3.6%)
Concomitant therapy (N˚; %)
• Azathioprine 14 (70%) 12 (42.7%)
• Local steroid 1 (5%) 2 (7.1%)
• Systemic steroid 1 (5%) 5 (17.9%)
• 5-aminosalycilate 7 (35%) 3 (15%)
UC-ulcerative colitis; CD–Crohn’s Disease
https://doi.org/10.1371/journal.pone.0172916.t001
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these cases. (Fig 3) ROC analysis was performed to calculate the accuracy of previously deter-
mined 2.0 μg/ml cut-off value of TL for prediction of long-term therapeutic response. Serum
IFX levels showed better correlation with the current status than with the long-term efficacy.
Fig 1. Serum IFX levels immediately prior the administration of regular maintenance infliximab (IFX)
infusion (trough level, TL), as well as 2 (W2aTL) and 6 weeks (W6aTL) afterwards in the adequate and
inadequate responder group.
https://doi.org/10.1371/journal.pone.0172916.g001
Fig 2. ROC analysis of IFX trough levels (TL) associated with current and long-term response.
https://doi.org/10.1371/journal.pone.0172916.g002
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Fig 3. Incorrectly classified cases by serum infliximab trough levels after 6-months follow-up.
https://doi.org/10.1371/journal.pone.0172916.g003
Table 2. Results of logistic regression analysis for prediction current (at inclusion) and long-term response (after 6-months follow-up).
LOGISTIC REGRESSION FOR PREDICTION CURRENTS RESPONSE
(Overall model fit: Nagelkerke R2 = 0.668; Goodness-of-fit: Hosmer and Lemeshow Test p = 0.300;
Classification table: Correctly predictions = 85.4%)
B S.E. df p OR = Exp(B) 95% CI for OR
TL 1.81 0.64 1 0.005 6.137 1.75–21.53
W2aTL -0.07 0.03 1 0.013 0.928 0.88–0.99
W6aTL 0.41 0.33 1 0.217 1.506 0.79–2.88
ATI 0.18 1.44 1 0.900 1.198 0.07–20.03
Constant -3.94 1.37 1 0.004 0.019
LOGISTIC REGRESSION FOR PREDICTION LONG-TERM RESPONSE
(Overall model fit: Nagelkerke R2 = 0.438; Goodness-of-fit: Hosmer and Lemeshow Test p = 0.221;
Classification table: Correctly predictions = 77.1%)
B S.E. df p OR = Exp(B) 95% CI for OR
TL 1.26 0.48 1 0.008 3.515 1.38–8.96
W2aTL -0.05 0.02 1 0.020 0.953 0.92–0.99
W6aTL 0.15 0.22 1 0.505 1.160 0.75–1.8
ATI 0.46 0.99 1 0.644 1.585 0.23–11.18
Constant -1.99 0.87 1 0.022 0.136
B: regression coefficient; S.E.: standard error; df: degree of freedom; OR: odds ratio; CI: confidence interval; TL: serum infliximab [IFX] trough level;
W2aTL: serum IFX level 2 weeks after TL; W6aTL: serum IFX level 6 weeks after TL; ATI: antibody-to-infliximab
https://doi.org/10.1371/journal.pone.0172916.t002
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The sensitivity and specificity in the prediction of long-term response was 70.8% and 75.0%
(AUC: 76.5%). (Fig 2) Prediction rate in logistic regression model was 77.1%, which correlated
with the results of ROC analysis. (Table 2)
ATI positivity
ATI was identified in 11 patients with low serum IFX levels (<1 μg/ml). In 9 cases antibodies
were not detectable in all of the three consecutive blood samples, suggesting that the expres-
sion of ATI in the blood was transient. Single sampling of ATI showed a nonsignificant trend
for the correlation with the therapeutic response. The proportion of ATI positivity in the ade-
quate and inadequate responder groups was 5.0% vs. 28.5% (p = 0.060) immediately prior
administration of regular maintenance IFX infusion, but two and six weeks after the biological
therapy it was 5.0% vs. 7.1% (p = 0.684) and 5.0% vs. 21.0% (p = 0.089). Using the three points’
measurements, ATI expression showed significant difference between the adequate and inade-
quate responder groups (5.0% vs 35.7%; p = 0.016). (Fig 4) In one of the ATI positive, adequate
responder patients, allergic reaction occurred during the subsequent regular IFX infusion.
After the 6-months follow-up clinical remission was achieved in three cases, when IFX 5 mg/
kg therapy was combined with perianal surgical treatment (seton drainage). Four patients
Fig 4. Proportion of ATI positivity in the adequate and inadequate responder groups.
https://doi.org/10.1371/journal.pone.0172916.g004
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showed partial response to biological therapy. In three cases acute flare-up was observed,
requiring surgery or switching to another biological agent. (Fig 5)
Discussion
Our prospective study of IBD patients receiving maintenance IFX therapy aimed to determine
the optimal timing and frequency of serum IFX and ATI measurements for the prediction of
therapeutic response. We found that determination of serum IFX level prior to the administra-
tion of regular IFX infusion and ATI positivity showed strong correlation with disease activity
and predicted the at least 6-months-long response. Measurement of serum IFX 2 or 6 weeks
after the infusion did not result in further elevation in the prediction rate.
Most studies have suggested that the measurement of serum IFX levels immediately after
induction or during maintenance therapy may help to optimize biological treatment since it
may help to decide about the necessity of dose escalation, cessation of therapy or the switching
to another biological drug. A multicenter retrospective study of 16 severe and 16 moderately
severe UC patients has detected significantly lower IFX TL in the acute severe UC group com-
pared to the moderately severe group [13]. The post hoc analysis of ACCENT I study carried
out by Cornillie et al. revealed higher median week 14 serum IFX TL in patients with sustained
response to scheduled maintenance IFX 5 mg/kg without dose escalation compared to those
who lost response during the 54-week follow-up: 4.0 vs 1.9 μg/ml. The optimal cut-off value
for predicting therapeutic response was3.5 μg/ml at week 14 [14]. This study did not con-
firm whether serum IFX level predicts therapeutic response in patients receiving IFX 10 mg/
kg. On the contrary, Paul et al. found significant increase in IFX TL (considered as a positive
Fig 5. Antibody-to-infliximab (ATI) positive cases after 6-months follow-up.
https://doi.org/10.1371/journal.pone.0172916.g005
Measurement of serum infliximab and anti-infliximab antibody level
PLOS ONE | https://doi.org/10.1371/journal.pone.0172916 March 31, 2017 8 / 11
delta IFX) in patients who responded to dose escalation. The delta IFX after drug optimization
was 2.2 μg/ml versus 0.2 μg/ml in the responder and nonresponder groups. The 0.5 μg/ml cut-
off delta IFX was independently associated with mucosal healing (likelihood ratio 2.02; 95%
CI, 1.01–4.08; p = 0.048) [15]. In the majority of previous studies timing of measurement is
not uniform. Week 14, after induction therapy is one of the most accepted sampling time, but
it is applicable only in case of newly administered IFX therapy to predict long-term response
especially in questionable cases. In other studies, samples were taken in various times (at week
22, 30, 52 or 54) or at the time of relapse. Currently there is no evidence-based recommenda-
tion about the optimal timing of measurement of serum IFX levels in patients who receive
maintenance biological therapy. The meta-analysis of 22 studies carried out by Moore et al.
in 2016 has found that the>2μg/ml cut-off trough IFX level during maintenance therapy is
associated with greater probability of clinical remission (risk ratio RR 2.9, 95% CI 1.8–4.7,
p<0.001) and mucosal healing (RR 3.0, 95% CI 1.4–6.5, p = 0.004) [16]. The main limitation
of this analysis was that inclusion criteria and the time of sampling was not uniform. In our
study we found that the measurement of serum IFX level was effective in the prediction of
therapeutic response only prior to the administration of regular IFX infusion, and that multi-
ple sampling (W2aTL and W6aTL) did not result in further increase in the prediction rate.
The 2.0 μg/ml cut-off IFXw0 value showed slightly better correlation with the current condi-
tion than with long-term response: sensitivity and specificity were 71.4% and 85% vs. 70.8% vs.
75.0%. It is important to highlight that partial response or loss of response were observed only
in three patients with2.0 μg/ml TL during 5 or 10 mg/kg IFX maintenance therapy. It sug-
gests that the measurement of serum IFX levels may be a great predictor of response both in
case of normal dose of IFX therapy and after dose escalation.
Antibody formation against IFX may be observed in 60% of patients with episodic adminis-
tration and in 6–25% of cases with scheduled biological therapy [8,17]. Based on the results of
Ungar et al. ATI-free survival can be achieved by 42% of patients by 4-years follow-up, and in
90% of the cases the antibody appears within the first 12 months of therapy [18]. Use of con-
comitant immunosuppressants such as azathioprine and methotrexate may result in a 50%
reduction in the risk of developing ATI (p<0.00001) [19]. The assessment of 13 studies with
data of 1378 patients found that the risk of loss of response to IFX therapy in ATI positive IBD
patients is elevated: risk ratio was 3.2 (95% CI: 2.0–4.9, p<0.0001), when compared with the
ATI negative group [9]. ATI formation was associated with lower serum IFX levels. The stan-
dardized mean difference in trough serum IFX levels between groups was −0.8 (95% CI: −1.2,
−0.4, p<0.0001). Furthermore, the presence of ATI increases the rate of infusion reactions and
serum sickness–like reactions [20]. In the study of O’Meara et al. the risk ratio of any acute
infusion reaction and severe infusion reactions was 2.4 (95% CI: 1.5–3.8, p<0.001) and 5.8
(95% CI: 1.7–19, p = 0.004) in ATI positive patients when compared with patients without
ATI, but the rate of delayed hypersensitivity reactions did not differ significantly between the
groups [7]. Baert et al. determined that the optimal cut-off serum ATI concentration for the
prediction of shorter duration of response and infusion reactions is 8.0 μg/ml [21]. In our
study ATI formation was observed in 11 patients, and was associated with lower serum IFX
levels in all of the cases. The proportion of ATI was higher in the inadequate responder group,
but only the three points’ measurement was able to establish significant difference between the
groups. ATI formation may increase the risk of loss of response, but could not exclude the
opportunity of clinical remission particularly after dose escalation or during combined surgical
and medical therapy. Therefore, in case of ATI positivity overall assessment of symptoms,
serum IFX levels and therapeutic response considering subjective judgment is required.
Our results suggest that the simultaneous measurement of IFX TL and ATI titers signifi-
cantly increase the diagnostic accuracy for the therapeutic decision in uncertainly responding
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patients. The measurement of W2aTL and W6aTL levels does not improve further the accu-
racy of the prediction of therapeutic response, but results in substantially elevated costs. The
expression of ATI in the circulation may be transient, therefore single sampling is supposed to
be insufficient for predicting the therapeutic response. It increases the risk of loss of response,
but does not exclude the optimal response to normal or escalated dose of IFX. We recommend
simultaneous assessment of serum IFX and ATI levels together with the clinical condition of
patients. Clinical response based on the subjective judgment of the attending physician always
takes priority over the results of measurement.
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